Tulchinsky Marciano Cohen Levitski & Co advised RedHill Biopharma on the deal.
RedHill Biopharma (RDHL Nasdaq), signed a License agreement for Talicia with Galean Medical Trade for sale and distributing in the United Arab Emirate.
Talicia is a U.S. FDA-approved treatment for a bacterial infection that affects more than 50% of the world’s adult population.
RedHill will receive an upfront payment of $2 million and is eligible for additional milestone payments as well as tiered royalties up to mid-teens on sales of Talicia in the UAE.
The Tulchinsky Marciano Cohen Levitski & Co team was led by partner Adv. Gershon (Glenn) Shalom-Winter (Picture).
Involved fees earner: Gershon Shalom-Winter – Tulchinsky Marciano Cohen Levitski & Co;
Law Firms: Tulchinsky Marciano Cohen Levitski & Co;
Clients: RedHill Biopharma;
